FCGR3A and breast carcinoma: For instance, the chimeric FcγRIIIa-FcεRIγ (CD16/γ) or CD16-CD3ζ receptors (cCD16ζ) were successfully used in combination with anti-CD20 mAb rituximab in T cells and NK cells to confer cytotoxicity against malignant B cells [141, 143] or in combination with anti-Her2/neu mAb trastuzumab in NK cell model cell line NK-92 to kill breast cancer cell lines [141].